CIBRA Capital’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
Other funds holding ESPR
CIBRA Capital's ESPR Position: Q3 2026 in Review
CIBRA Capital sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 164,614 shares — an estimated $520K sold.
CIBRA Capital first reported a position in ESPR in Q2 2026 and held it in 1 quarter. The position peaked at $520K in Q2 2026. 2 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.
- CIBRA Capital reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
- CIBRA Capital sold 164,614 Esperion Therapeutics shares in Q3 2026, an estimated $520K.
- CIBRA Capital first reported a position in Esperion Therapeutics in Q2 2026 and held it in 1 quarter.
- CIBRA Capital's Esperion Therapeutics position peaked at $520K in Q2 2026.
- 2 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.
Based on CIBRA Capital's 13F filing for Q3 2026, filed 19 Nov 2026.